Advertisement

Topics

Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations

19:00 EST 15 Jan 2014 | NIH

CDC researchers have developed methods of producing unlimited quantities of Group-C (GpC) rotavirus antigens. GpC rotaviruses are a major, worldwide cause of acute gastroenteritis in children and adults that is distinct from Group-A rotavirus. However, GpC rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GpC rotavirus disease. Consequently, the true clinical burden of GpC rotavirus disease has not been clearly established.

This technology allows for the expression of the three major capsid proteins (VP2, VP6 and VP7) of GpC rotavirus by recombinant baculovirus and assembly of virus-like particles (2-6-7 and/or 6-7) within insect cells. Further, this CDC generated technology allows for the large-scale access to GpC rotavirus antigens, previously infeasible, and will permit use of these novel virus-like particles for the development of rotavirus diagnostic assays and improved vaccine formulations.

IC: 
CDC
NIH Ref. No.: 
E-191-2013/2
TAB No: 
TAB-2720
Advantages: 
  • Permits large-scale production of Group-C rotavirus antigens, previously impractical
  • Produced virus-like particles/antigens can be used for rotavirus vaccines, other immunogenic uses and/or sero-diagnostic assay development
  • Diagnostic tools for Group-C rotavirus are currently unavailable; this technology fulfills an unmet need for accurate assessment of the Group-C rotaviral global health burden
Applications: 
  • Development or improvement of rotavirus vaccines
  • Rotavirus vaccine composition research
  • Childhood illness vaccination programs and rotavirus monitoring endeavors
  • Development of novel rotavirus diagnostic tools
Development Status: 

In vitro data available

Provider Technology ID: 
2720
Updated On: 
Nov 7, 2017
Provider Classifications: 
Date Published: 
Thursday, January 16, 2014
Patent Application: 
PCT/US2009/045688
12/995,024
Publications: 
Patent Authority: 
PCT
US
2016-03-02 00:00:00
2016-03-02 00:00:00
Patent Number: 
9,169,296
Licensing Contacts: 
LPM Address: 
  --
United States
Lead Inventor: 
Inventor IC: 
CDC
LPM FIrst Name: 
Karen
LPM Last Name: 
Surabian
LPM Address: 
BG 5601FL RM 2G48 MSC 9804 5601 FISHERS LN
LPM City: 
Bethesda
LPM Zip: 
20892-9804
Inv Is lead: 
LPM State: 
MD
LPM Phone: 
301-594-9719
LPM Suffix: 
J.D., M.B.A.
LPM Organization: 
NIH Office of Technology Transfer
LPM Fax: 
240-627-3117
DTDT Classification: 
Infectious Diseases
Diagnostics
Viral
Non-AIDS (only)
Therapeutics
Anti-virals
Non-AIDS (only)
Vaccines
Adjuvants/Vectors/Modulators
Viral
Non-AIDS (only)
Infectious Diseases (viral)
Zoonotic/Veterinary
Others
Diagnostic
Monitoring (Public Health/Counterfeit Detection/Biological)
Research Tool
Other (this will include others such as manufacturing, consumer products and vet
Antibody
Biomarker
In vitro data available
DTDT Description: 
Infectious Diseases
Infectious Diseases - Diagnostics
Infectious Diseases - Diagnostics - Viral
Infectious Diseases - Diagnostics - Viral: Non-AIDS
Infectious Diseases - Therapeutics
Infectious Diseases - Therapeutics - Anti-virals
Infectious Diseases - Therapeutics - Anti-virals: Non-AIDS
Infectious Diseases - Vaccines
Infectious Diseases - Vaccines: Adjuvants/Vectors/Modulators
Infectious Diseases - Vaccines - Viral
Infectious Diseases - Vaccines - Viral: Non-AIDS
Infectious Diseases (viral)
Zoonotic/Veterinary
Others
Diagnostic
Monitoring (Public Health/Counterfeit Detection/Biological)
Research Tool
Other (this will include others such as manufacturing, consumer products and vet
Antibody
Biomarker
In vitro data available
Pat Filing Date: 
2009-05-29
2011-01-26
Patent Issue Date: 
2015-10-27
Publication Link: 
http://www.ncbi.nlm.nih.gov/pubmed/19285329
Publication Caption: 
PMID 19285329
Publication Title: 

Clark KB, et al.

Additional Patents: 
Various international filings pending and/or deferred
Technology Term: 
Development Stage Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Related Patents: 
8,822,192
8,357,525
9,498,526
Related Patent Publish Date: 
1467349200
1507093200
1242104400
1273640400
1320991200
1188882000
1220504400
1267682400
1355810400
1408338000
Related Patent Application: 

15/200,837

15/725,221

61/177,393

PCT/US2010/034537

13/320,095

60/969,826

PCT/US2008/075239

12/676,490

13/718,648

14/461,663

Related Patent Authority: 
US
US
EIR
US
PCT
US
US
PCT
US
US
US
Related Invention: 
E-122-2013/0
E-150-2013/0
E-153-2013/0
E-521-2013/0
E Number Only: 
E-191-2013
Inventor First Name: 
Baoming
Inventor Last Name: 
Jiang

Original Article: Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations

NEXT ARTICLE

More From BioPortfolio on "Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...